Association of eNOS gene polymorphisms with renal disease in Caucasians with type 2 diabetes  by Santos, Kátia G. et al.
Association of eNOS gene polymorphisms with renal 
disease in Caucasians with type 2 diabetes
Ka´tia G. Santos a,b,*, Daisy Crispim c, Luı´s H. Canani c, Paula T. Ferrugema,
Jorge L. Gross c, Israel Roisenberg d
a Research Center in Medical Sciences, Universidade Luterana do Brazil, Canoas, Brazil
b Cardiology Division, Hospital de Clı´nicas de Porto Alegre, Porto Alegre, Brazil
c Endocrinology Division, Hospital de Clı´nicas de Porto Alegre, Porto Alegre, Brazil
d Department of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
d i a b e t e s r e s e a r c h and c l i n i c a l p r a c t i c e 9 1 ( 2 0 1 1 ) 3 5 3 – 3 6 2
a r t i c l e i n f o
Article history:
Received 26 September 2010 
Received in revised form
12 December 2010 
Accepted 21 December 2010 
Published on line 21 January 2011
Keywords:
Type 2 diabetes 
Renal disease 
Diabetic nephropathy 
Endothelial nitric oxide synthase 
(eNOS)
Polymorphism
a b s t r a c t
Aim: In this study we investigated if the 786T > C, the VNTR intron 4 a/b and the 894G > T
(Glu298Asp) polymorphisms in the eNOS gene were associated with renal disease in 617 type 
2 diabetic Caucasian-Brazilians. These polymorphisms were also examined in 100 Cauca-
sian healthy blood donors.
Methods: Genotyping of eNOS polymorphisms was performed by PCR or PCR-RFLP and 
haplotype frequencies were estimated using a Bayesian method. Logistic regression analy-
sis was done to test for association of eNOS polymorphisms with susceptibility to renal 
involvement (microalbuminuria, macroalbuminuria or end-stage renal disease). This anal-
ysis was carried out assuming three diferent genetic models for the minor allele, adjusting 
for possible effect modifiers.
Results: Genotype and allele frequencies in patients with renal disease were not signifi-
cantly different from those of patients with normoalbuminuria and healthy blood donors for 
all eNOS polymorphisms. Likewise, there were no differences in haplotype frequencies 
among healthy blood donors and type 2 diabetic patients with or without renal involvement 
(P > 0.05 for all comparisons).
Conclusion: No associations between the 786T > C, the VNTR intron 4 a/b and the 894G > T
(Glu298Asp) polymorphisms in the eNOS gene and renal disease were observed in type 2 
diabetic Caucasian-Brazilians.
# 2010 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
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Diabetic nephropathy (DN) is the leading cause of chronic 
kidney disease in patients starting renal replacement therapy 
and it is associated with increased cardiovascular mortality. 
Although poor glycemic control and arterial hypertension are 
strong risk factors for this complication [1], several lines of* Corresponding author at: Programa de Po´s-Graduac¸a˜o em Diagno´stico 
Farroupilha, 8001, Pre´dio 22, 58 andar, 92425-900, Canoas, RS, Brazil. T
E-mail address: kgsantos2010@gmail.com (K.G. Santos).
0168-8227/# 2010 Elsevier Ireland Ltd. Open access under the Elsevier OA license
doi:10.1016/j.diabres.2010.12.029evidence have suggested that its development also depends on 
genetic factors [1–3]. The endothelial nitric oxide synthase 
(eNOS) has been considered to be a potential candidate gene for 
susceptibility to DN since chromosome 7q35 was indicated as 
a candidate region containing genes for susceptibility to this 
complication of diabetes in Pima Indians [4] and in Caucasians 
and non-Caucasians [5].Gene´tico e Molecular, Universidade Luterana do Brazil (ULBRA), Av. 
el.: +55 51 34774000x2668; fax: +55 51 34774000x2668.
.
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the regulation of vascular tone. It exerts vasoprotective effects
by scavenging superoxide radicals and suppressing platelet
aggregation, leukocyte adhesion and smooth muscle cell
proliferation [6]. Therefore, a reduction in basal NO release
may predispose individuals to vascular abnormalities, such as
hypertension and atherosclerosis. On the other hand, over-
production can also damage cells and tissues because NO
increases the accumulation of reactive oxygen species, which
in turn leads to atherogenesis [6,7]. In the endothelium, NO is
mainly synthesized by the eNOS isoform, a constitutive
enzyme whose expression is regulated by several factors,
such as cytokines and smoking [7].
Variants of the eNOS gene have been shown to modify its
expression or activity [8], thus leading to reduced or excessive
NO production and consequently contributing to many
pathological processes. Among the several polymorphisms
identified in the eNOS gene, three have been subjects of
intensive research in relation to microvascular complications
of diabetes, namely, the 786T > C substitution in promoter
region (rs2070744), the tandem repeat of 27 bp in intron 4
(VNTR intron 4 a/b) and the 894G > T (Glu298Asp) missense
substitution in exon 7 (rs1799983). These polymorphisms have
been found to be associated with different stages of DN,
ranging from an increase of albuminuria up to end-stage renal
disease (ESRD) in diabetic patients on hemodialysis [9–22].
However, several other authors have not found any associa-
tions of eNOS polymorphisms with DN [23–35]. Moreover, a
recent meta-analysis of candidate gene population-based
association studies relating variants of eNOS gene to the risk
of presenting DN or the so-called diabetes leading to severe
nephropathy (DSN) showed no association of eNOS poly-
morphisms with both DN and DSN in type 2 diabetes, except
for 894G > T variant [36].
Therefore, considering that DN is a complex disease with
multifactorial etiology and that eNOS polymorphisms show a
marked population variability in their distributions, the aim of
this study was to evaluate whether the 786T > C, the VNTR
intron 4 a/b and the 894G > T (Glu298Asp) polymorphisms in
the eNOS gene are associated with renal disease (micro-,
macro-albuminuria and end-stage renal disease) in Cauca-
sian-Brazilians with type 2 diabetes.
2. Subjects, materials and methods
2.1. Subjects
This case–control study was carried out on 617 unrelated
Caucasian-Brazilian type 2 diabetic patients participating in a
multicentric study in the Brazilian State of Rio Grande do Sul.
All Caucasian-Brazilians were subjects of European origin
(mainly from Portugal, Spain, Italy, and Germany). Type 2
diabetes was diagnosed according to the American Diabetes
Association criteria [37]. Cases were defined by increased
urinary albumin excretion (UAE) (micro- and macro-albumin-
uria) or ESRD. Controls were patients with normoalbuminuria
and known diabetes duration of at least 10 years.
Patients underwent a standardized clinical and laboratory
evaluation that consisted of a questionnaire, physical exami-nation, and laboratory tests. Weight and height were used to
calculate body mass index (BMI) (kg/m2). Blood pressure was
measured after a 5-min rest in the sitting position using a
standard mercury sphygmomanometer. Arterial hypertension
was defined as blood pressure levels 140/90 mmHg, and
patients being treated with antihypertensive medication whose
blood pressure was lower than 140/90 mmHg were also
considered hypertensive. Details about the onset of smoking
and the cessation of smoking in ex-smokers were recorded with
a questionnaire. Patients who were ex- or current-smokers
were considered as having a positive history of smoking and
they were compared with those who never smoked.
Assessment of DR was performed by ophthalmoscopic
examination through dilated pupils. DR was graded as absent,
non-proliferative, or proliferative [38]. In relation to renal
status, cases were defined based on the UAE in at least two of
three consecutive 24-h timed or random spot sterile urine
collections for 76% and 24% of the patients, respectively.
Patients were classified as having normoalbuminuria (UAE
<20 mg/min or <17 mg/l) (n = 241), microalbuminuria (UAE
20–199 mg/min or 17–174 mg/l) (n = 171), macroalbuminuria
(UAE 200 mg/min or >174 mg/l) (n = 95), or ESRD by the
presence of chronic renal disease treated by dialysis when
other causes of proteinuria or renal disease were ruled out
(n = 110).
Venous blood samples were collected for biochemical
analyses after a 12-h fast. Glycated hemoglobin was measured
by an ion-exchange HPLC procedure (reference range:
4.7–6.0%). Serum creatinine concentrations were determined
by Jaffe´’s reaction and AER by immunoturbidimetry (Sera-Pak
immuno microalbuminuria; Bayer, Tarrytown, USA). Total
cholesterol, HDL cholesterol and triglycerides were measured
by standard enzymatic methods.
In order to estimate the allele frequencies in the general
population, the 786T > C, the VNTR intron 4 a/b and the
894G> T polymorphisms were also examined in 100 Cauca-
sians recruited among volunteer healthy blood donors
(50 females, 50 males; mean age, 46.4 9.6 years) from the
Hospital de Clı´nicas de Porto Alegre (Porto Alegre, Brazil). All
subjects participating in this study provided written informed
consent, the protocol for which was approved by all hospital
ethics committees.
2.2. eNOS genotyping
DNA was extracted from peripheral blood leukocytes by a
salting out procedure [39]. Gene fragments containing the
786T > C (rs2070744) and the 894G > T (Glu298Asp)
(rs1799983) variant sites in the eNOS gene were amplified by
polymerase chain reaction (PCR) using the primers and
conditions as previously described by Tanus-Santos et al.
[40]. The amplification products were digested with the
appropriate restriction enzymes under the conditions recom-
mended by the manufacturer (MBI Fermentas, St. Leon-Rot.,
Germany). The digested fragments were then separated by
electrophoresis in 6% polyacrylamide gels, followed by
ethidium bromide staining and direct visualization under
ultraviolet light. To improve genotyping accuracy, samples
with known genotypes were used in each batch as positive
controls to evaluate the completeness of PCR product
Table 1 – PCR primers, reaction conditions and restriction enzymes for the genotyping of eNOS polymorphisms.
Polymorphism Primer sequence Annealing
temperature
for PCR
PCR product
(bp)
Restriction
enzyme
Restriction
enzyme digest
fragment (bp)
Reference
786T > C 50-TGGAGAGTGCTGGTGTACCCCA-30 60 8C 180 MspI T: 140 + 40 [40]
50-GCCTCCACCCCCACCCTGTC-30 C: 90 + 50 + 40
VNTR intron
4 a/b
50-AGGCCCTATGGTAGTGCCTTT-30 58 8C 393 (a allele) [13]
50-TCTCTTAGTGCTGTGGTCAC-30 420 (b allele)  
447 (c allele)
894G > T
(Glu298Asp)
50-AAGGCAGGAGACAGTGGATGGA-30 59 8C 248 Eco24I
(BanII)
G: 163 + 85 [40]
50-CCCAGTCAATCCCTTTGGTGCTCA-30 T: 248
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by PCR using primers and conditions that were previously
described [13], and the alleles were identified according to the
length of bands after separation of PCR fragments in ethidium
bromide-stained 2% agarose gels. Genotyping was performed
by laboratory personnel who were unaware of clinical
characteristics of the patients and the details of genotyping
method are shown in Table 1.
2.3. Statistical analyses
Comparisons between diabetic patients with or without renal
involvement were accomplished using the unpairedStudent’s t-
test for normally distributed variables or the Mann–Whitney U-
test for variables with a skewed distribution (SPSS for Windows,
version 10.0). Allele frequencies were determined by gene
counting,anddeparturesfromtheHardy–Weinberg equilibrium
were verified using the x2-test. The x2-test and Fisher’s exactTable 2 – Clinical and demographic characteristics of type 2 di
Without (n = 2
Gender (% male) 35.3
Age (years) 62.0  9.4
Duration of diabetes (years) 16.7  6.8
Body mass index (kg/m2) 28.2  4.4
Hypertension (%) 75.3
Systolic blood pressure (mmHg) 143  23
Diastolic blood pressure (mmHg) 85  13
Antihypertensive medications (%)
ACEi 52.9
Diuretic 40.0
Beta-blocker 32.9
Calcium antagonists 20.0
Positive history of smoking (%) 40.0
Therapy for diabetes (% insuline use) 35.0
Glycated hemoglobin (%) 6.7  1.7
Serum creatinine (mmol/L) 80 (35–168)
Total cholesterol (mmol/L) 5.45  1.09
HDL cholesterol (mmol/L) 1.16  0.27
Triglycerides (mmol/L) 1.64 (0.39–7.44)
Diabetic retinopathy (%) 47.7
Data are reported as mean  SD, median (range), or percentage. P-values
tests, as appropriate. n = number of individuals. ACEi: angiotensin-conve
were ex- or current-smokers were considered as having a positive histotest, whichever appropriate, were usedto evaluate the alleleand
genotype distributions among groups of subjects.
Logistic regression analysis was done to test for associa-
tion of eNOS polymorphisms with type 2 diabetes, adjusting
for gender and age, and renal disease (comparison between
diabetic patients with renal involvement and diabetic
patients with normoalbuminuria), adjusting for demograph-
ic and clinical variables that could be possible effect
modifiers. These analyses were carried out assuming three
diferent genetic models for the minor allele (allele contrast,
dominant and recessive models), as proposed by some
investigators [41]. Power calculations (PEPI program, version
4.0 [42]) showed that this study had a power of approximately
80% at a significance level of 0.05 to detect an odds ratio of 1.65
for the three eNOS polymorphisms (patients with renal
disease compared to those with normoalbuminuria), under
a dominant model (genotypes carrying at least one minor
allele comparing to homozygote for major allele).abetic patients according to the presence of renal disease.
Renal disease P-value
41) With (n = 376)
57.2 0.001
60.4  9.7 0.047
15.0  9.1 0.003
28.7  5.0 0.366
85.2 0.004
148  25 0.072
87  14 0.420
57.7 0.566
53.2 0.068
23.7 0.165
30.8 0.099
47.9 0.069
50.0 0.001
6.6  1.9 0.529
97 (35–1193) <0.001
5.52  1.26 0.586
1.08  0.29 0.001
1.85 (0.50–16.60) 0.017
78.6 <0.001
were obtained by the unpaired Student’s t, Mann-Whitney U, or x2
rting-enzyme inhibitor. HDL: high-density lipoprotein. Patients who
ry of smoking.
Table 3 – Genotype and allele frequencies of eNOS polymorphisms in healthy blood donors and type 2 diabetic patients with or without renal disease, assuming three
diferent genetic models.
Polymorphism Blood donors Diabetes Diabetes
Without renal disease With renal disease
786T > C n = 100 n = 617 n = 241 n = 376
Genotypes
TT 42 (42.0) 233 (37.8) 93 (38.6) 140 (37.2)
TC 46 (46.0) 264 (42.8) 104 (43.2) 160 (42.6)
CC 12 (12.0) 120 (19.4) 44 (18.2) 76 (20.2)
P-value – 0.202a 0.364b 0.168c; 0.830d
Alleles
T 130 (65.0) 730 (59.2) 290 (60.2) 440 (58.5)
C 70 (35.0) 504 (40.8) 192 (39.8) 312 (41.5)
P-value – 0.137a 0.273b 0.113c; 0.605d
Odds ratio (95% CI) for the C allele
Allele contrast model
Univariate – 1.28 (0.93–1.77)a 1.23 (0.86–1.76)b 1.32 (0.94–1.85)c; 1.07 (0.84–1.36)d
Dominant model
Univariate – 1.20 (0.78–1.84)a 1.15 (0.72–1.85)b 1.22 (0.78–1.91)c; 1.06 (0.76–1.48)d
Multivariate – 1.20 (0.68–1.85)a 1.02 (0.54–1.93)b 1.07 (0.62–1.83)c; 0.91 (0.60–1.37)d
Recessive model
Univariate – 1.77 (0.94–3.34)a 1.64 (0.82–3.25)b 1.86 (0.97–3.57)c; 1.13 (0.75–1.71)d
Multivariate – 1.62 (0.79–3.34)a 1.90 (0.76–4.76)b 1.78 (0.83–3.79)c; 1.13 (0.70–1.83)d
VNTR intron 4 a/b n = 100 n = 583 n = 233 n = 350
Genotypes
bb 67 (67.0) 405 (69.5) 168 (72.1) 237 (67.7)
ba 30 (30.0) 158 (27.1) 59 (25.3) 99 (28.3)
aa 3 (3.0) 16 (2.7) 5 (2.2) 11 (3.1)
bc – 4 (0.7) 1 (0.4) 3 (0.9)
P-value – 0.881a 0.688b 0.976c; 0.678d
Alleles
a 36 (18.0) 190 (16.3) 69 (14.8) 124 (17.7)
b 164 (82.0) 972 (83.4) 396 (85.0) 573 (81.9)
c – 4 (0.3) 1 (0.2) 3 (0.4)
P-value – 0.755a 0.510b 0.922c; 0.456d
Odds ratio (95% CI) for the a allele
Allele contrast model
Univariate – 0.89 (0.59–1.35)a 0.89 (0.65–1.20)b 0.99 (0.64–1.52)c; 1.25 (0.90–1.75)d
Dominant model
Univariate – 0.86 (0.55–1.35)a 0.76 (0.46–1.27)b 0.93 (0.58–1.49)c; 1.22 (0.84–1.76)d
Multivariate – 0.81 (0.47–1.39)a 0.63 (0.31–1.26)b 0.89 (0.50–1.57)c; 1.28 (0.83–2.00)d
Recessive model
Univariate – 0.91 (0.26–3.18)a 0.70 (0.16–3.01)b 1.05 (0.29–3.83)c; 1.49 (0.51–4.33)d
Multivariate – 1.49 (0.23–9.80)a 2.05 (0.16–26.05)b 1.53 (0.21–10.92)c; 1.48 (0.41–5.40)d
894G > T (Glu298Asp) n = 100 n = 609 n = 235 n = 374
Genotypes
GG 47 (47.0) 294 (48.2) 118 (50.2) 176 (47.1)
GT 48 (48.0) 261 (42.9) 95 (40.4) 166 (44.4)
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TT 5 (5.0) 54 (8.9) 22 (9.4) 32 (8.5)
P-value – 0.351a 0.253b 0.471c; 0.628d
Alleles
G 142 (71.0) 849 (69.7) 331 (70.4) 518 (69.3)
T 58 (29.0) 369 (30.3) 139 (29.6) 230 (30.7)
P-value – 0.774a 0.955b 0.696c; 0.711d
Odds ratio (95% CI) for the T allele
Allele contrast model
Univariate – 1.06 (0.76–1.50)a 1.03 (0.70–1.50)b 1.09 (0.76–1.55)c; 1.06 (0.82–1.37)d
Dominant model
Univariate – 0.95 (0.62–1.45)a 0.88 (0.55–1.40)b 1.00 (0.64–1.55)c; 1.14 (0.82–1.57)d
Multivariate – 0.95 (0.57–1.56)a 0.79 (0.42–1.49)b 1.01 (0.60–1.72)c; 1.18 (0.79–1.76)d
Recessive model
Univariate – 1.85 (0.72–4.74)a 1.96 (0.72–5.34)b 1.78 (0.67–4.68)c; 0.91 (0.51–1.60)d
Multivariate – 1.37 (0.46–4.06)a 1.48 (0.36–6.15)b 1.30 (0.41–4.06)c; 0.84 (0.44–1.63)d
Genotype and allele frequencies are shown as number (%). n = number of individuals. P-values were obtained using the x2 or Fisher’s exact test, as appropriate. Odds ratios (ORs) with 95% confidence
intervals (95% CI) were obtained by logistic regression analysis. Multivariate logistic regression analysis was carried out controlling for gender and age for comparisons between type 2 diabetic patients
vs. healthy blood donors, type 2 diabetic patients without renal involvement vs. healthy blood donors and type 2 diabetic patients with renal involvement vs. healthy blood donors. For comparison
between type 2 diabetic patients with renal disease vs. patients with normoalbuminuria, multivariate logistic regression model was adjusted for gender, duration of diabetes, smoking (ever
smoked = 1, never smoked = 0), systolic blood pressure, insulin therapy (yes = 1, no = 0) and tryglicerides levels. Allele contrast model: Minor allele vs. major allele. Dominant model: genotypes
carrying the minor allele vs. homozygous genotype for major allele. Recessive model: homozygous genotype for the minor allele vs. genotypes carrying major allele. As the c allele (VNTR intron 4a/b
polymorphism) was very rare, carriers of this allele were excluded from the logistic regression analysis.
a Type 2 diabetic patients vs. healthy blood donors.
b Type 2 diabetic patients without renal disease vs. healthy blood donors.
c Type 2 diabetic patients with renal disease vs. healthy blood donors.
d Type 2 diabetic patients with renal disease vs. patients with normoalbuminuria.
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Table 4 – Haplotype frequencies of eNOS polymorphisms in healthy blood donors and type 2 diabetic patients with or without renal disease.
Haplotype Blood donors Diabetes Diabetes
Frequencies S.E. Frequencies S.E. Z-score P-value Without
renal disease
With renal
disease
Z-score P-value
Frequencies S.E. Frequencies S.E.
n 200 1222 474 748
786T/4b/894G 98 (49.0) 0.009 555 (45.4) 0.004 0.87 0.384 227 (48.0) 0.006 325 (43.5) 0.005 1.48 0.139
786T/4b/894T 26 (13.0) 0.009 117 (9.6) 0.004 1.35 0.176 41 (8.6) 0.005 77 (10.3) 0.005 0.88 0.378
786T/4a/894G 8 (4.0) 0.008 50 (4.1) 0.003 0.00 >0.999 15 (3.1) 0.005 36 (4.8) 0.004 1.31 0.192
786T/4a/894T – – – – – – – – – – – –
786C/4b/894G 9 (4.5) 0.008 100 (8.2) 0.004 1.68 0.093 39 (8.2) 0.005 64 (8.5) 0.005 0.08 0.937
786C/4b/894T 31 (15.5) 0.009 248 (20.3) 0.004 1.49 0.137 97 (20.5) 0.006 152 (20.3) 0.005 0.01 0.991
786C/4a/894G 27 (13.5) 0.009 147 (12.0) 0.003 0.48 0.628 52 (11.0) 0.005 92 (12.3) 0.005 0.60 0.552
786C/4a/894T 1 (0.5) 0.005 5 (0.4) 0.002 0.00 >0.999 3 (0.6) 0.002 2 (0.3) 0.002 0.34 0.736
Permutation test – – 0.127a – 0.103b – 0.181c –
P-value 0.634d
Haplotype frequencies are shown as number (%). n = number of chromosomes. S.E. = standard error. PHASE program version 2.1 was used to estimate the haplotype frequencies and to compare
groups of subjects (cases and controls), computing P-values by a case–control permutation test. Individual haplotypes were compared between cases and controls using Z-score in PEPI program
version 4.0. As the c allele (intron 4 VNTR) was rare, carriers of this allele were excluded from the haplotype analysis and the VNTR intron 4 a/b polymorphism was considered as a bi-allelic marker.
a Type 2 diabetic patients vs. healthy blood donors.
b Type 2 diabetic patients without renal disease vs. healthy blood donors.
c Type 2 diabetic patients with renal disease vs. healthy blood donors.
d Type 2 diabetic patients with renal disease vs. patients with normoalbuminuria.
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calculated and expressed in terms of D0 and r2 [43]. Haplotype
frequencies were estimated by a Bayesian method using
PHASE version 2.1 [44,45]. We also used the PHASE program to
compare the distribution of different eNOS haplotypes
between groups of subjects through permutation analyses
of 1000 random replicates. Individual haplotypes were
compared between the groups by Z-score, using PEPI program.
A P-value < 0.05 was considered as statistically significant.
3. Results
3.1. Clinical and demographic characteristics
The clinical and demographic characteristics of type 2 diabetic
patients according to the presence or absence of renal
involvement are summarized in Table 2. Caucasian-Brazilians
with renal disease were more often male, younger, with a
shorter duration of diabetes, higher prevalence of hyperten-
sion, insulin therapy, and retinopathy, higher levels of serum
creatinine and triglycerides and lower levels of HDL choles-
terol as compared to patients with normoalbuminuria.
3.2. Genotype and allele frequencies
The genotype frequencies were in agreement with those
predicted by the Hardy–Weinberg equilibrium for all eNOS
polymorphisms in both type 2 diabetic patients and healthy
blood donors, except for the 786T > C polymorphism, in
which there was a lower frequency of heterozygotes than
expected among diabetic patients (expected frequen-
cy = 48.0% vs. observed frequency = 43.5%, P = 0.015). As
shown in Table 3, there were no statistically significant
differences when genotype and allele frequencies for the
786T > C, VNTR intron 4 a/b and 894G > T polymorphisms
were compared among healthy blood donors, type 2 diabetic
patients, diabetic patients with normoalbuminuria and
patients with renal involvement.
In order to test for an association of eNOS polymorphisms
with type 2 diabetes and renal disease, logistic regression
analyses were carried out assuming three diferent genetic
models for the minor allele. However, no relationship of the
three eNOS polymorphisms with type 2 diabetes or renal
involvement was observed. Even after adjusting for demo-
graphic and clinical variables, the results were only slightly
modified (Table 3). Considering that the inclusion of patients
with microalbuminuria in the group of subjects with renal
disease might result in underestimating the magnitude of an
association, all statistical procedures were repeated excluding
these patients from analyses. Again, results remained almost
identical to those previously obtained.
3.3. Haplotype analysis
Based on two different measures of linkage disequilibrium
(LD), D0 and r2, it could be inferred that the three eNOS
polymorphisms were in weak LD among healthy blood donors
(D0 = 0.658 and r2 = 0.177, for 786T > C vs. VNTR intron 4 a/b;
D0 = 0.326 and r2 = 0.081, for 786T > C vs. 894G > T;D0 = 0.885 and r2 = 0.070, for VNTR intron 4 a/b vs.
894G > T). Despite some moderate D0 values, the r2 values
were very low. Likewise, in type 2 diabetic patients the eNOS
polymorphisms were also in weak LD (D0 = 0.584 and r2 = 0.098,
for 786T > C vs. VNTR intron 4 a/b; D0 = 0.486 and r2 = 0.153,
for 786T > C vs. 894G > T; and D0 = 0.834 and r2 = 0.057, for
VNTR intron 4 a/b vs. 894G > T).
Next, using a Bayesian method to estimate the frequency
of different haplotypes composed of the three studied eNOS
polymorphisms, we investigated whether a specific haplo-
type is associated with type 2 diabetes or with renal disease.
As the c allele of the VNTR polymorphism in intron 4 was very
rare (only 4 out of 583 diabetic patients and none of the
healthy blood donors carried this allele in heterozygosis),
carriers of the c allele were excluded from haplotype analysis
and the VNTR intron 4 a/b polymorphism was considered as a
bi-allelic marker. A total of seven haplotypes resulting from
the three eNOS polymorphisms was observed in both type 2
diabetic patients and healthy blood donors (Table 4). The
haplotype frequencies in diabetic patients were not signifi-
cantly different from those of healthy blood donors. More-
over, among diabetic patients, the haplotype frequencies
were also similar between subjects with or without renal
involvement and they were not different from those of
healthy blood donors (Table 4).
4. Discussion
In the present study, no associations between the 786T > C,
the VNTR intron 4 a/b and the 894G > T (Glu298Asp)
polymorphisms in the eNOS gene and the presence or severity
of renal disease were observed in Caucasian-Brazilians with
type 2 diabetes. As a matter of fact, elucidating the role of eNOS
polymorphisms in the development or progression of kidney
disease in type 2 diabetes has proven to be a challenging area
of investigation, with many studies reporting controversial
results [9–36].
In relation to the786T > C polymorphism in the promoter
region, the C allele was found to be associated with a greater
degree of albuminuria in European American families [15],
with an increased risk of DN in North Asian Indians [9] and
with ESRD in Japanese [11]. However, three studies did not
observe an association of this polymorphism with renal
insufficiency in Tunisians [14], Japanese [30] and North and
South Asian Indians [22] with type 2 diabetes, as also observed
in the meta-analysis by Zintzaras et al. [36] and in the present
study for Caucasian-Brazilians.
The VNTR intron 4 a/b variant has been the most studied
eNOS polymorphism in the pathogenesis of renal insufficiency
in both diabetic and nondiabetic patients, predominantly in
Asian populations. Some authors have found an association of
the a allele with ESRD in Poles [13] and Brazilians from the
Southeast region [12], with progression of chronic renal failure
in the Japanese [10], and with DN in the Japanese [17] and
North Asian Indians [9]. However, most studies have observed
that the VNTR in intron 4 is not related to the different stages
of DN (from increased albuminuria up to ESRD treated by
dialysis) in African-American [25], German [24], Polish [27],
Hellen (from Greece and Cyprus) [28], Tunisian [14], North and
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[11,16,18,26,31–33,35] type 2 diabetic patients. In our study, the
VNTR intron 4 a/b polymorphism was not associated with
renal disease in Caucasian-Brazilians from the Southern
region, which also corroborates the results of the meta-
analysis by Zintzaras et al. [36].
Of the three eNOS variants analyzed in the present study,
the 894G > T (Glu298Asp) polymorphism in exon 7 has
provided the most controversial results in relation to renal
outcomes in type 2 diabetic patients. The T allele was found to
be associated with an increased risk of deterioration of renal
function in Korean [19], ESRD in Indonesian [21] and Japanese
[16,18,20], and DN in North Asian Indian [9] and Tunisian [14]
type 2 diabetic patients. Also, the T allele was shown to be
weakly associated with DN and DSN in patients with type 2
diabetes and it was strongly associated with DSN in East
Asians in the meta-analysis [36]. In contrast, the GG genotype
was recently associated with an increased risk of chronic renal
insufficiency (CRI) in a South Asian Indian population with
type 2 diabetes, whereas such an association was not observed
among North Asian Indians in the same study [22]. Moreover,
several other authors did not find any association of the
polymorphism in exon 7 with renal insufficiency in African
American [25], European American [15], Finnish [34], Austra-
lian [23], and Japanese [30,32] type 2 diabetic patients, as also
observed in the present study for Caucasian-Brazilians.
Among the several factors which could have contributed to
the discrepancies between the above-mentioned studies, the
definition of outcome itself and the criteria of inclusion seem to
be a major factor. For instance, considering only the tens of
studies reported in the Japanese population, it is worthwhile to
note that in those which analyzed the association of eNOS
polymorphisms in relation to ESRD as the main endpoint, with
the sample study composed of patients with and without
diabetes (30–40% diabetic patients in most reports), and
comparing both diabetic and nondiabetic patients on hemodi-
alysis to healthy controls, a trend towards a positive association
was observed [10,11,16,18,20,35]. On the other hand, a trend
towards no association was detected in those studies that
utilized DN as the outcome (the entire study sample composed
of diabetic patients) [26,30–33]. This trend was also observed in
two studies by the same Polish research group [13,27]. First,
Ksiazek et al. [27] reported that the frequency of the a allele
(VNTR intron 4 a/b polymorphism) was similar among diabetic
patients with or without DN, although both groups of patients
presented a higher frequency of this allele compared to healthy
controls. Later, Buraczynska et al. [13] observed an increased
frequency of theaallele among ESRDpatients, both diabetic and
nondiabetic, in comparison to healthy controls.
In the present study, 21% of the subjects with renal
impairment did not have DR, which suggests that other renal
disease could be the cause of increased UAE other than DN
[46]. In the study by Christensen et al. [46], 31% of patients with
overt proteinuria and normal fundoscopy who were submitted
to kidney biopsy based on clinical indication did not have DN
(13.7% had glomerulonephritis and 17.6% normal glomerular
structure). Considering this proportion, in our sample only
6.3% of cases (30% of 21% without DR) would have nondiabetic
nephropathy. This is a very small number of subjects that
probably did not have an important effect in the final resultsand conclusions. As a matter of fact, we repeated the analyses
with only those with increased albuminuria and DR, and the
results remained virtually the same (data not shown).
Apart from this, ethnic differences have often been evoked
as being partly responsible for the discrepancies between
studies regarding the association of eNOSpolymorphisms with
ESRD and DN [14,21,24,28,36]. However, even reports from the
same country have presented conflicting results, as reported
in North Asian Indians [9,22]. In fact, population studies have
shown marked interethnic differences in the distribution of
eNOS variants [40,47]. Therefore, the linkage disequilibrium
observed between the eNOS polymorphisms may be responsi-
ble, at least in part, for the controversial findings observed
between these polymorphisms and DN.
In this context, the most recent studies have investigated
the effect of different haplotypes in order to obtain a more
comprehensive analysis of the role of eNOS gene polymorph-
isms in the susceptibility to DN [9,14,22]. Unfortunately, the
findings remain unclear. For instance, Ahluwalia et al. [9]
reported that the haplotype with all the major alleles (786T/
4b/894G) was found to be associated with a decreased risk of
DN in North Asian Indians, whereas Ezzidi et al. [14] reported
that the 786T/4b/894T haplotype was associated with an
increased risk of DN in Tunisians. Moreover, Tiwari et al. [22]
observed an excess of the haplotype carrying the 894G allele
(786T/4b/894G) in type 2 diabetic patients with CRI as
compared to patients without this condition in a South Indian
population. The authors hypothesized that CRI subjects
carrying the 894T allele might not have survived, possibly
due to the premature mortality caused by cardiovascular
events, with the 894G allele conferring greater survival ability
to comorbid complications. On the other hand, Shin Shin et al.
[19] found that, in a retrospective cohort study of Koreans with
overt nephropathy, deterioration of renal function was faster
and renal survival was lower in patients with the 894GT
genotype than in those with the GG genotype.
In the present study, the haplotype frequencies of patients
with renal involvement were not different from those with
normoalbuminuria. In our study, although the 786C, 4a and
894T alleles were as frequent as in other Caucasian popula-
tions [40,47,48], the haplotype frequencies differed from those
observed in Brazilian Caucasians from the Southeast region
[47] but were similar to those found in Caucasians from the
United States [40], indicating that our population is less
admixed than Caucasians from the Southeast region.
Apart from this, DN is a disorder of multifactorial
inheritance [1–3]. Thus, the existence of gene-environment
interactions may explain the discrepancy of results among
different studies, as already recognized in literature [36].
Moreover, it is also possible that the eNOS polymorphisms
exert only a weak to moderate effect on the development of
this complication. Thus, one possible limitation of the present
study is that a factor with a small effect would require a bigger
sample size to be detected. This limitation, however, does not
seem to be a contributing factor in the present study, since we
obtained an approximately 80% statistical power of detecting
an odds ratio as low as 1.65 for any of the three eNOS
polymorphisms. By comparison, an order of magnitude lower
than has been found in most studies of DN or ESRD
[9,12,13,15,17,18,20–22].
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intron 4 a/b or the 894G > T (Glu298Asp) polymorphisms in the
eNOS gene with renal disease was observed in Caucasian-
Brazilians with type 2 diabetes. Likewise, no association
between eNOS polymorphisms and the presence of type 2
diabetes itself was observed. Considering that studies
designed to investigate the relationship of eNOS polymorph-
isms in the development of renal dysfunction have shown
very controversial results, it is early to define its role in the
pathogenesis of this diabetic complication. Further large,
multiethnic and prospective studies should be performed to
clarify the relationship of the 786T > C, VNTR intron 4 a/b
and 894G > T (Glu298Asp) polymorphisms in the eNOS gene
with kidney disease in type 2 diabetic patients.
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